CAS: 150192-39-5; (2-Bromo-5-Methoxyphenyl)Methanol

相似化合物

2737-20-4 22921-68-2 7507-86-0

上下游产品

2-bromo-5-methoxy-benzaldehyde 2-bromo-5-methoxy-benzoic acid methyl 2-bromo-5-methoxybenzoate (2-amino-5-methoxyphenyl)methanol 2-bromo-5-methoxybenzyl chloride 2-bromo-5-methoxy-benzaldehyde (2-iodo-5-methoxyphenyl)methanol 2-bromo-5-methoxybenzyl bromide

间甲氧基苯甲醇置于n-溴代丁二酰亚胺(Nbs)体系中,用 乙腈 用作溶剂,以94%的收率获得2-溴-5-甲氧基苄醇
参考文献:改良的hoveyda-Grubbs复分解催化剂中含有螯合的碘代亚苄基配体的有趣的取代基作用†
标题:改良的hoveyda-Grubbs复分解催化剂中含有螯合的碘代亚苄基配体的有趣的取代基作用†
摘要:制备并表征了一系列改性的结合了碘代亚苄基配体的hoveyda-Grubbs催化剂.发现在碘化物对位的吸电子环取代基会降低催化活性,这表明ru⋯i-ar键的解离不是决定速率的步骤.
Doi:10.1039/c2Dt32422A

专利信息

专利号:US-2002107391-A1
优先权日:2000-10-25
标 题:Process for the synthesis of an endothelin receptor antagonist
发明人：FREY LISA F; CHEN CHENG Y; LI JING; SONG ZHIGUO J; TAN LUSHI; TILLYER RICHARD D; TSCHAEN DAVID M; ZHAO MATTHEW M
摘要:The present invention relates to a practical and efficient way to synthesize the compound for the endothelin receptor antagonist involving a Grignard addition and a cyclization reaction to give a desired compound of the general formula shown below:

专利号:US-6172235-B1
优先权日:1996-08-09
标题 :Asymmetric conjugate addition reaction
发明人：DOLLING ULF H; FREY LISA F; TILLYER RICHARD D; TSCHAEN DAVID M
权利人:MERCK & CO INC
摘要:This invention relates to a key intermediate in the synthesis of an endothelin antagonist and the synthesis of this key intermediate using an asymmetric conjugate addition reaction.

专利号:US-6353110-B1
优先权日:1997-08-08
标 题:Asymmetric conjugate addition reaction
发明人：DEVINE PAUL N; TILLYER RICHARD D; HEID JR RICHARD M; TSCHAEN DAVID M
权利人:MERCK & CO INC
摘要:This invention relates to a key intermediate in the synthesis of an endothelin antagonist the synthesis of this key intermediate via an asymmetric conjugate addition reaction.

专利号:US-7989438-B2
优先权日:2007-07-17
标题 :Therapeutic compounds
发明人：CONTE IMMACOLATA; HABERMANN JOERG; MACKAY ANGELA; NARJES FRANK; RICO FERREIRA MARIA DEL ROSARIO; STANSFIELD IAN
权利人:ANGELETTI P IST RICHERCHE BIO
摘要:A class of macrocyclic compounds of formula (I), wherein R 7 , A, Ar, B, D, F, M, Q 1 , Q 2 , W, X, Y and Z are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection.